Compare Enveric Biosciences Inc (ENVB) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Trip.com Group Ltd — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Trip.com Group Ltd trades at $38.91 (market cap $23.75B). The key difference: Trip.com Group Ltd is far larger — about 3492.6× Enveric Biosciences Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Trip.com Group Ltd for 79 Days on average.
| ENVB | TCOM | |
|---|---|---|
Market Cap | $6.80M | $23.75B |
Volume | 64,867 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $78.96 |
52-Week Low | $1.27 | $37.96 |
Typical Hold Time | 14 Days | 79 Days |
Enterprise Value | -$1.49M | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
Trip.com (TCOM) trades at $38.90, up 2.13% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $1.07, beating expectations, with revenue growth of 6% year-over-year. Valuation metrics appear attractive with P/E of 7.34 and P/S of 2.6, while maintaining robust profitability with 36.9% net income margin and 15.74% ROE.
Despite regulatory headwinds from recent antitrust penalties, Trip.com's international expansion and strong cash flow generation support long-term growth. The stock faces near-term technical pressure but offers fundamental value with 45.6% upside to the $56.64 consensus price target. Key risks include regulatory scrutiny and competitive pressures in the travel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
